- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Generalised myasthenia gravis (gMG)
- Meeting Date: November 2025
- Public Summary Document (PSD) March 2025 - November 2025 PBAC Meetings - (PDF 949KB)
- Public Summary Document (PSD) March 2025 - November 2025 PBAC Meetings - (Word 443KB)
Rozanolixizumab – November 2025
Rozanolixizumab: Solution for subcutaneous infusion 280 mg in 2 mL (140 mg per mL); Rystiggo® - November 2025
Last updated
5 November 2025